The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen
Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.
 
Jason Alan Chesney
Consulting or Advisory Role - Amgen
Research Funding - Amgen
Travel, Accommodations, Expenses - Amgen
 
Igor Puzanov
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Merck
 
Merrick I. Ross
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen; Merck
Travel, Accommodations, Expenses - Amgen; Merck
 
Frances A. Collichio
Consulting or Advisory Role - Amgen (Inst)
Research Funding - Amgen (Inst); Mayo Phase II (Inst); Morphotek (Inst); Novartis (Inst); Vascular Biogenics (Inst)
Travel, Accommodations, Expenses - Amgen
 
Mohammed M. Milhem
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Genentech; Novartis
 
Lisa Chen
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Jenny J. Kim
No Relationships to Disclose
 
Claus Garbe
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Philogen; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Philogen; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar Therapeutics, Philogen, Provectus, Regeneron; Novartis; OncoSec; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar Therapeutics, Philogen, Provectus, Regeneron; Novartis; OncoSec; Roche
 
Robert Hans Ingemar Andtbacka
Honoraria - Amgen; Merck/Schering Plough
Consulting or Advisory Role - Amgen; Merck/Schering Plough
Research Funding - Amgen (Inst); OncoSec (Inst); Takara Bio (Inst); Viralytics (Inst)